Andang Miatmoko, - and Ester Adelia Mianing, - and Retno Sari, - and Esti Hendradi, - (2021) Nanoparticles use for Delivering Ursolic Acid in Cancer Therapy: A Scoping Review. Frontiers in Pharmacology, 12. pp. 1-19. ISSN 1663-9812

	Text (FULLTEXT) C-08 Artikel.pdf Download (9MB)
	Text (KUALITAS KARIL) C-08 Kualitas Karil.pdf Download (487kB)
	Text (SIMILARITY) C-08 Similarity.pdf Download (5MB)
	Text (KORESPONDENSI) C-08 Korespondensi.pdf Download (1MB)

Abstract

Ursolic acid is a natural pentacyclic triterpenoid that exerts a potent anticancer effect. Furthermore, it is classified as a BCS class IV compound possessing low permeability and water solubility, consequently demonstrating limited bioavailability in addition to low therapeutic effectiveness. Nanoparticles are developed to modify the physical characteristics of drug and can often be produced in the range of 30–200 nm, providing highly effective cancer therapy due to the Enhanced Permeation and Retention (EPR) Effect. This study aims to provide a review of the efficacy and safety of various types of Ursolic Acid-loading nanoparticles within the setting of preclinical and clinical anticancer studies. This literature study used scoping review method, where the extracted data must comply with the journal inclusion criteria of within years of 2010–2020. The identification stage produced 237 suitable articles. Duplicate screening was then conducted followed by the initial selection of 18 articles that had been reviewed and extracted for data analysis. Based on this review, the use of nanoparticles can be seen to increase the anticancer efficacy of Ursolic Acid in terms of several parameters including pharmacokinetic data, survival rates and inhibition rates, as well as the absence of serious toxicity in preclinical and clinical trials in terms of several parameters including body weight, blood clinical chemistry, and organ histipathology. Based on this review, the use of nanoparticles has been able to increase the anticancer efficacy of Ursolic Acid, as well as show the absence of serious toxicity in preclinical and clinical trials. Evenmore, the liposome carrier provides development data that has reached the clinical trial phase I. The use of nanoparticle provides high potential for Ursolic Acid delivery in cancer therapy.

Actions (login required)

View Item